# Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx

> **NCT00051441** · PHASE3 · COMPLETED · sponsor: **McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.** · enrollment: 605 (actual)

## Conditions studied

- Stomatitis
- Radiation Effects

## Interventions

- **DRUG:** Benzydamine Hydrochloride 0.15% Oral Rinse

## Key facts

- **NCT ID:** NCT00051441
- **Lead sponsor:** McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 605 (ACTUAL)
- **Last updated:** 2011-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051441, "Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00051441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*